Antibody-Oligonucleotide Conjugates (AOCs)

ADC-Related Custom Services

Antibody-Oligonucleotide Conjugate (AOC) consists of three parts: antibody, linker and oligonucleotide. AOC combines the tissue-specific targeting of antibody drugs with the target-specific capabilities of small nucleic acids, addressing the limitation of current small nucleic acid drugs that mainly target the liver through LNP and GalNAc delivery systems.

References:

[1]. Dugal-Tessier J, Thirumalairajan S, Jain N. Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates. J Clin Med. 2021;10(4):838.

Antibody-Oligonucleotide Conjugates (AOCs) Related Products (3):

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-177453

Basivarsen
Basivarsen (DYNE-101 oligomer) is composed of an antisense oligonucleotides and a linker (HY-177454). It is designed to target mutant nuclear myotonic dystrophy protein kinase (DMPK) RNA for RHase H-mediated degradation to correct splicing. It is used for the study of myotonic dystrophy type 1 (DM1).

HY-177452

Zeleciment basivarsen
Zeleciment basivarsen (DYNE-101) is an antibody-oligonucleotide conjugate (AOC) that consists of a TfR1-binding Fab Zeleciment (HY-P990780) conjugated to an antisense oligonucleotide Basivarsen (HY-177453). This conjugate designed to target mutant nuclear myotonic dystrophy protein kinase (DMPK) RNA for RHase H-mediated degradation to correct splicing. It is used for the study of myotonic dystrophy type 1 (DM1).

HY-P990780

Zeleciment		98.85%
Zeleciment is an anti-TFRC IgG1κ monoclonal antibody.

Name
Email *

	Sorry, but the email address you supplied was invalid.